CFRX - ContraFect Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

ContraFect Corporation

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
United States

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger James Pomerantz FACP, M.D., F.A.C.P.Chairman, CEO & Pres65kN/A1957
Ms. Natalie Bogdanos J.D.Gen. Counsel, Corp. Sec. & Data Protection Officer540.63kN/A1969
Dr. Cara CassinoChief Medical Officer and Exec. VP of R&D766.14kN/A1962
Mr. Michael Messinger CPA, CPACFO & Chief Accounting OfficerN/AN/A1975
Ms. Nancy DongVP of Fin. & Admin.N/AN/A1965
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Corporate Governance

ContraFect Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.